| Code | CSB-RA980158MB5HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Affecizx, targeting vascular endothelial growth factor (VEGF), a critical signaling protein that regulates angiogenesis and vascular permeability. VEGF plays a pivotal role in physiological processes including wound healing and embryonic development, while also driving pathological neovascularization in various disease states. Aberrant VEGF signaling is implicated in cancer progression through tumor angiogenesis, age-related macular degeneration, diabetic retinopathy, and other conditions characterized by abnormal blood vessel formation.
Affecizx (aflibercept) functions as a VEGF trap, binding VEGF-A, VEGF-B, and placental growth factor (PlGF) with high affinity to inhibit their interaction with native receptors, thereby strongly inhibiting abnormal angiogenesis and vascular leakage. It has been approved globally and is effective in treating diseases such as wet age-related macular degeneration through intravitreal injection. This biosimilar provides researchers with a valuable tool for investigating VEGF-mediated pathways, studying angiogenesis mechanisms, evaluating anti-angiogenic therapeutic strategies, and exploring vascular biology in disease models. The antibody supports diverse experimental approaches in oncology, ophthalmology, and cardiovascular research where VEGF signaling modulation is of scientific interest.
There are currently no reviews for this product.